Eidos Therapeutics Prices IPO, To Debut Today
San Francisco-based Eidos Therapeutics, a clinical stage biopharaceuticals firm focused on diseases caused by transthyretin (TTR) amyloidosis (ATTR), priced its IPO last night, saying it will sell 6,250,000 shares of its common stock at $17.00 per share. The company will start trading this morning on the Nasdaq Global Select Market as EIDX. The IPO was underwritten by J.P. Morgan, BofA Merrill Lynch, and Barclays. Eidos Therapeutics was majority owned by BridgeBio Pharma.
posted on Wednesday, June 20, 2018
Related stories:
> Audentes Therapeutics Prices IPO
> eHealth Prices IPO
> PEAR Therapeutics Gets $50M For Treating Substance Abuse With Software
> Fitbit Prices IPO
> Square Prices IPO At $9.00 Per Share
silicontap.com Home